Bruce Allan Hay

This inventor holds 27 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: General Electric Company, Nammi Therapeutics, Inc., Nanopharmaceuticals LLC. Active years: 2013-2026.

USPTO Granted Patents = 27 (Patent Applications = 10)

% Patents Active = 92.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 18(Granted Patents)

Company Filing History:

13 out of 52,359

General Electric Company

patents

10 out of 11

Nammi Therapeutics, Inc.

patents

3 out of 21

Nanopharmaceuticals LLC

Years Active: 2013-2026

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702695 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2026-08-11),

2. 12653829 - Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereof (2026-06-16),

3. 12624109 - αv-integrin targeted small molecule drug conjugates (2026-05-12),

4. 12311010 - Formulated and/or co-formulated liposome compositions containing toll-like receptor('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2025-05-27),

5. 12286403 - Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof (2025-04-29),

6. 12059470 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2024-08-13),

7. 11896646 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2024-02-13),

8. 11833209 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-12-05),

9. 11801304 - Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-10-31),

10. 11744874 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-09-05),

11. 11723888 - Polymer conjugated thyrointegrin antagonists (2023-08-15),

12. 11679141 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-06-20),

13. 11186551 - Composition of scalable thyrointegrin antagonists with improved retention in tumors (2021-11-30),

14. 10961204 - Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors (2021-03-30),

15. 10450345 - Method of isolation of polypeptide-aptamer-polymer conjugates (2019-10-22),

Title: The Inventor Bruce Allan Hay: Pioneering Innovations in Niskayuna

Introduction: Bruce Allan Hay is a distinguished inventor based in Niskayuna, NY, known for his groundbreaking contributions to various technological fields.

Latest Patents: Bruce Allan Hay holds several patents in the areas of renewable energy, sustainable materials, and advanced electronics, showcasing his commitment to driving innovation forward.

Career Highlights: With a career spanning over two decades, Bruce Allan Hay has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Bruce Allan Hay has collaborated with top engineers, scientists, and researchers, fostering a culture of creativity and excellence that has led to numerous successful projects.

Conclusion: Bruce Allan Hay's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.